Production of dendritic cell vaccines using different methods with equivalent results: Implications for emerging centers
Hematol., Transfus. Cell Ther. (Impr.); 46 (1), 2024
Publication year: 2024
Introduction Dendritic cell (DC) vaccines have demonstrated good efficacy in preventing relapse and in increasing survival of patients affected by a variety of both solid and hematological tumors. Most protocols used to generate these cells involve the automated separation of peripheral blood monocytes from patients. This approach requires specialized equipment, which elevates the cost of this type of therapy, potentially limiting the widespread access to patients.